Verifyle and The Oregon Association of Tax Consultants Partner to Protect Tax Consultants and Their Clients from the Growing Threat of Data Theft
We're proud to announce another partnership! Our newest partner is OATC. Please to see another organization that cares about providing valuable benefits to their members.
Share
'Our members are more aware than ever of the increasing threat from phishing and other cyber-attacks,' said Cathy Johnson, President of OATC. 'Verifyle is a great fit for OATC members because it's both extremely secure and very simple for both our members and their taxpayer clients to use.'
'In today's environment where data breaches and cyberattacks are increasingly common, tax and accounting professionals absolutely need a secure channel for sharing sensitive documents and communications with their clients,' said Jack Smith, CEO of Verifyle. 'Through our partnership with OATC, we're able to offer their members that essential peace of mind—knowing that client data remains private and protected at all times. We're honored that OATC selected Verifyle as their trusted security partner.'
Unlike many other cloud-storage and cloud-sharing services, which use a single master key for encrypting and decrypting their users' data, Verifyle's Cellucrypt® technology uses password-derived keys on top of a public-key system to individually encrypt data objects, adding several additional layers of protection for their users. With the additional option to disable password reset, Verifyle becomes the most secure cloud-sharing platform available, while remaining extremely simple to use.
About Verifyle
Verifyle delivers ultra-secure messaging, document sharing, and digital signatures, all from a simple, single-screen interface. Verifyle was built from the ground up to be the most secure cloud-sharing solution, and to deliver improved productivity and control of information to its users. Verifyle's industry-leading, patented encryption technology gives users the highest level of security, protecting them from bulk-access vulnerability through the unique encryption of each document and thread.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
16 minutes ago
- Business Insider
Don't Expect Apple Stock (AAPL) to Pop Until AI and Tariff Uncertainty Ease, Say Analysts
Apple (AAPL) stock was higher today after analysts largely gave a thumbs up to its strong Q3 results, but investors shouldn't expect a huge uptick until AI and tariff overhangs are dealt with. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The tech giant yesterday announced earnings per share (EPS) of $1.57, which topped consensus expectations of $1.43. Revenue in the April through June quarter came in at $94.04 billion, beating Wall Street forecasts of $89.53 billion. The Silicon Valley-based company also reported that its iPhone sales grew 13% year-over-year during the quarter and its overall revenue grew 10%, the largest quarterly revenue growth since December 2021. Time for AI Krish Sankar, five-star TipRanks-rated analyst at TD Cowen, reiterated his Buy rating on the stock and kept a $275 price target. 'Revenue growth was better than feared, driven by above seasonal iPhone and Mac demand,' he said. He said that concerns over Apple's 'incomplete AI strategy' were an ongoing overhang for the stock but that the company has around 18 months to 'rectify' this. 'The personalized Siri is still on track for a 2026 release and Apple has increased AI retail spend across research and development,' he said. ' While investors are understandably focused on Apple's lack of leadership in AI models and Agentic AI systems, the declining cost to access models can be leveraged.'. Morgan Stanley analyst Erik Woodring raised the firm's price target on Apple to $240 from $235 and kept a Buy rating. He said Apple's report was its strongest quarterly report in over two years. Historically, he said this would be a quarter 'where bulls get louder,' but he doesn't expect Apple to 'break out until clarity emerges on tariffs and regulation.' Srini Pajjuri, analyst at Raymond James, raised the firm's price target on Apple to $240 from $230 and kept an Outperform rating. He was encouraged by accelerating capex spend and expects Apple Intelligence, including the much-awaited Siri update, to drive a multiyear upgrade cycle. Valuation Risk Needham analyst Laura Martin reiterated her Hold rating. She said the impressive financial performance was overshadowed by concerns about the company's future growth prospects. This included the anticipated delay in the integration of Apple Intelligence until after 2025 and the competitive pressure from Android's advancements. She highlighted the risk associated with Apple's heavy reliance on the iPhone, suggesting that if Apple's iOS system lags significantly behind Android, it could pose a substantial valuation risk for the company. Indeed, the group has struggled in comparison with its peers over the last 12 months. Is AAPL a Good Stock to Buy Now? On TipRanks, AAPL has a Moderate Buy consensus based on 13 Buy, 12 Hold and 1 Sell ratings. Its highest price target is $275. AAPL stock's consensus price target is $228.11, implying an 8.09% upside.
Yahoo
21 minutes ago
- Yahoo
Roadzen Subsidiary Partners with Major UK Car Retailer to Offer Integrated GAP Insurance
Roadzen Inc. (NASDAQ:RDZN) is one of the tech stocks to buy according to analysts. On July 15, Roadzen announced that its wholly-owned UK-based subsidiary, called Global Insurance Management Limited/GIM, partnered with one of the UK's largest independent retailers of nearly new cars and vans. The collaboration will offer GAP Insurance to the retailer's over 60,000 annual vehicle buyers as part of their vehicle purchase process. Through the partnership, Roadzen's advanced technology and insurance infrastructure will power a fully integrated Return to Invoice/RTI GAP insurance solution. The solution will be embedded directly into the UK retailer's digital and in-store sales process. Insurance house, car and family health live concept. The insurance agent presents the toys that symbolize the coverage. The partnership is facilitated by Roadzen's Global Distribution Network/GDN platform, which provides real-time pricing, policy issuance, payment collection, and claims processing through a single, seamless digital interface for clients. Roadzen Inc. (NASDAQ:RDZN) operates an Insurtech company in India, the US, the UK, and Europe. It serves insurers, reinsurers, agents, brokers, carmakers, dealerships, fleets, taxicab companies, ridesharing platforms, and other distribution channels. While we acknowledge the potential of RDZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
3 hours ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
